ATE502110T1 - Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie - Google Patents

Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Info

Publication number
ATE502110T1
ATE502110T1 AT07825556T AT07825556T ATE502110T1 AT E502110 T1 ATE502110 T1 AT E502110T1 AT 07825556 T AT07825556 T AT 07825556T AT 07825556 T AT07825556 T AT 07825556T AT E502110 T1 ATE502110 T1 AT E502110T1
Authority
AT
Austria
Prior art keywords
mycobacterial
hypoxia
expression
application
promoter active
Prior art date
Application number
AT07825556T
Other languages
English (en)
Inventor
Gilles Marchal
Mohammad Abolhassani
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE502110T1 publication Critical patent/ATE502110T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT07825556T 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie ATE502110T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291205A EP1882741B1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie
PCT/IB2007/003300 WO2008012693A2 (en) 2006-07-25 2007-07-25 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Publications (1)

Publication Number Publication Date
ATE502110T1 true ATE502110T1 (de) 2011-04-15

Family

ID=37026080

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06291205T ATE472602T1 (de) 2006-07-25 2006-07-25 Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie
AT07825556T ATE502110T1 (de) 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06291205T ATE472602T1 (de) 2006-07-25 2006-07-25 Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie

Country Status (9)

Country Link
US (2) US20090304637A1 (de)
EP (2) EP1882741B1 (de)
JP (1) JP2009544305A (de)
AT (2) ATE472602T1 (de)
CA (1) CA2658713A1 (de)
DE (2) DE602006015180D1 (de)
DK (1) DK1882741T3 (de)
ES (1) ES2347812T3 (de)
WO (1) WO2008012693A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140598A2 (en) * 2006-12-04 2008-11-20 Bacilligen, Inc. Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
EP2620159A1 (de) 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
AU2013299643A1 (en) * 2012-08-10 2015-03-26 Memorial Sloan-Kettering Cancer Center Predicting bladder cancer responsiveness to BCG
US10494665B2 (en) * 2014-08-20 2019-12-03 Huawei Yang Test kit and method for testing target nucleic acid in sample
US20200237936A1 (en) 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
EP1523331B1 (de) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutisches vakzin gegen tuberkulosis
EP2206514B1 (de) * 2003-10-16 2014-01-08 The Regents of The University of California Rekombinante, intrazelluläre, immunogene Pathogenzusammensetzungen und Verwendungsverfahren
JP5090741B2 (ja) * 2003-12-02 2012-12-05 インスティティ・パスツール 新規なｓａｒｓ関連コロナウイルス系統のゲノムによりコードされるタンパク質及びペプチドの利用

Also Published As

Publication number Publication date
JP2009544305A (ja) 2009-12-17
CA2658713A1 (en) 2008-01-31
US20090304637A1 (en) 2009-12-10
DK1882741T3 (da) 2010-10-11
EP2049667A2 (de) 2009-04-22
ES2347812T3 (es) 2010-11-04
US20120156169A1 (en) 2012-06-21
DE602006015180D1 (de) 2010-08-12
WO2008012693A2 (en) 2008-01-31
EP2049667B1 (de) 2011-03-16
EP1882741A1 (de) 2008-01-30
WO2008012693A3 (en) 2008-04-24
ATE472602T1 (de) 2010-07-15
EP1882741B1 (de) 2010-06-30
DE602007013248D1 (de) 2011-04-28
HK1112753A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
DE602007013248D1 (de) Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie
EP3533877A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
MY167232A (en) Polypeptides binding to human complement c5
AU2018256498A1 (en) Antibodies to amyloid beta
MX361259B (es) Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
PH12017550023A1 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
SI2079481T1 (sl) Cepivo peptidnih kombinacij proti alergiji na maäśke
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
NZ600974A (en) Binding members for human cytomegalovirus
MX2015005253A (es) Metodo novedoso para tratar el daño a la medula espinal utilizando el fragmento de hmgb1.
EP2207052A4 (de) Material zur abdeckung, beschichtung oder abschirmung zum augenschutz und zur therapie vor den effekten von blauem licht
EP2166845A4 (de) Alpha-connexin-c-terminale (act) peptide für die behandlung der altersbedingten makulardegeneration
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
IL290817A (en) Methods for production of human recombinant arginase 1 and uses thereof
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MY173174A (en) Short bio-active peptides for promoting wound healing
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
EA201100610A1 (ru) Эффективная экспрессия укороченного человеческого белка rnaset2 в e.coli
IL212719A0 (en) Gold nanoparticles coated with polyelectrolytes and use thereof as medicament for the treatment of neurodegenerative diseases caused by protein aggregates
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties